{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T11:13:41Z","timestamp":1724757221904},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T00:00:00Z","timestamp":1568678400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s00393-019-00707-z","type":"journal-article","created":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T11:04:04Z","timestamp":1568718244000},"page":"13-22","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Aktuelle Therapie der axialen Spondyloarthritis","Current treatment of axial spondylarthritis"],"prefix":"10.1007","volume":"79","author":[{"given":"U.","family":"Kiltz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,17]]},"reference":[{"issue":"6","key":"707_CR1","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde\u00a0D, Ramiro\u00a0S, Landewe\u00a0R, Baraliakos\u00a0X, Van den Bosch\u00a0F, Sepriano\u00a0A et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76(6):978\u2013991","journal-title":"Ann Rheum Dis"},{"key":"707_CR2","volume-title":"S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Fr\u00fchformen","author":"U Kiltz","year":"2013","unstructured":"Kiltz\u00a0U, Sieper\u00a0J, Rudwaleit\u00a0M, Kellner\u00a0H, Krause\u00a0D, B\u00f6hle\u00a0E et al (2013) S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Fr\u00fchformen. https:\/\/www.awmf.org\/leitlinien\/detail\/ll\/060-003.html . Zugegriffen: 29.03.2019"},{"issue":"9","key":"707_CR3","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/annrheumdis-2018-213585","volume":"77","author":"AK Rausch Osthoff","year":"2018","unstructured":"Rausch Osthoff\u00a0AK, Niedermann\u00a0K, Braun\u00a0J, Adams\u00a0J, Brodin\u00a0N, Dagfinrud\u00a0H et\u00a0al (2018) 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis 77(9):1251\u20131260","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s00393-019-0619-6","volume":"78","author":"J Braun","year":"2019","unstructured":"Braun\u00a0J, Schwarting\u00a0A, Hammel\u00a0L, Legeler\u00a0C, Wimmer\u00a0P, Farber\u00a0L et al (2019) Medical care situation of patients with ankylosing spondylitis and psoriatic arthritis in Germany: Medical care situation of patients with spondyloarthritis (SpA): ankylosing spondylitis (AS) and psoriatic arthritis (PsA) from the perspective of rheumatologists in private practice and hospitals in Germany-Results of the research project \u201cSpA Loop-Life of Outpatients\u201d. Z\u00a0Rheumatol 78(4):372\u2013381. https:\/\/doi.org\/10.1007\/s00393-019-0619-6","journal-title":"Z Rheumatol"},{"issue":"7","key":"707_CR5","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","volume":"49","author":"C Escalas","year":"2010","unstructured":"Escalas\u00a0C, Trijau\u00a0S, Dougados\u00a0M (2010) Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a\u00a0meta-analysis. Rheumatology (Oxford) 49(7):1317\u20131325","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"707_CR6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.berh.2015.04.031","volume":"28","author":"J Braun","year":"2014","unstructured":"Braun\u00a0J, Baraliakos\u00a0X, Regel\u00a0A, Kiltz\u00a0U (2014) Assessment of spinal pain. Best Pract Res Clin Rheumatol 28(6):875\u2013887","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"707_CR7","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12891-016-1275-5","volume":"17","author":"E Balazcs","year":"2016","unstructured":"Balazcs\u00a0E, Sieper\u00a0J, Bickham\u00a0K, Mehta\u00a0A, Frontera\u00a0N, Stryszak\u00a0P et\u00a0al (2016) A randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord 17(1):426","journal-title":"BMC Musculoskelet Disord"},{"key":"707_CR8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/1471-2474-12-165","volume":"12","author":"PM Peloso","year":"2011","unstructured":"Peloso\u00a0PM, Gammaitoni\u00a0A, Smugar\u00a0SS, Wang\u00a0H, Moore\u00a0AR (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord 12:165","journal-title":"BMC Musculoskelet Disord"},{"issue":"3","key":"707_CR9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/rheumatology\/38.3.235","volume":"38","author":"M Dougados","year":"1999","unstructured":"Dougados\u00a0M, Gueguen\u00a0A, Nakache\u00a0JP, Velicitat\u00a0P, Veys\u00a0EM, Zeidler\u00a0H et al (1999) Ankylosing spondylitis: what is the optimum duration of a\u00a0clinical study? A one year versus a\u00a06\u00a0weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 38(3):235\u2013244","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"707_CR10","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper\u00a0J, Listing\u00a0J, Poddubnyy\u00a0D, Song\u00a0IH, Hermann\u00a0KG, Callhoff\u00a0J et al (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a\u00a0randomised multicentre trial (ENRADAS). Ann Rheum Dis 75(8):1438\u20131443","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"707_CR11","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders\u00a0A, Heijde\u00a0D, Landewe\u00a0R, Behier\u00a0JM, Calin\u00a0A, Olivieri\u00a0I et\u00a0al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a\u00a0randomized clinical trial. Arthritis Rheum 52(6):1756\u20131765","journal-title":"Arthritis Rheum"},{"issue":"10","key":"707_CR12","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1136\/annrheumdis-2012-201370","volume":"71","author":"F Kroon","year":"2012","unstructured":"Kroon\u00a0F, Landewe\u00a0R, Dougados\u00a0M, van der Heijde\u00a0D (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623\u20131629","journal-title":"Ann Rheum Dis"},{"key":"707_CR13","first-page":"CD008872","volume":"11","author":"AN Colebatch","year":"2011","unstructured":"Colebatch\u00a0AN, Marks\u00a0JL, Edwards\u00a0CJ (2011) Safety of non-steroidal anti-inflammatory drugs, including aspirin and paracetamol (acetaminophen) in people receiving methotrexate for inflammatory arthritis (rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, other spondyloarthritis). Cochrane Database Syst Rev 11:CD8872","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"707_CR14","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3899\/jrheum.150721","volume":"43","author":"FP Kroon","year":"2016","unstructured":"Kroon\u00a0FP, van der Burg\u00a0LR, Ramiro\u00a0S, Landewe\u00a0RB, Buchbinder\u00a0R, Falzon\u00a0L et\u00a0al (2016) Nonsteroidal antiinflammatory drugs for axial Spondyloarthritis: a Cochrane review. J\u00a0Rheumatol 43(3):607\u2013617","journal-title":"J Rheumatol"},{"key":"707_CR15","volume-title":"Nichtsteroidale Antirheumatika, aktualisierte Empfehlungen zur Verordnung","author":"W Bolten","year":"2009","unstructured":"Bolten\u00a0W, Kr\u00fcger\u00a0K, Reiter\u00a0S (2009) Nichtsteroidale Antirheumatika, aktualisierte Empfehlungen zur Verordnung. https:\/\/www.dgrh.de\/Start\/Publikationen\/Empfehlungen\/Medikation\/Nichtsteroidale-Antirheumatika.html . Zugegriffen: 29.03.2019"},{"issue":"5","key":"707_CR16","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/ard.2010.128660","volume":"70","author":"G Burmester","year":"2011","unstructured":"Burmester\u00a0G, Lanas\u00a0A, Biasucci\u00a0L, Hermann\u00a0M, Lohmander\u00a0S, Olivieri\u00a0I et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a\u00a0multidisciplinary European expert panel. Ann Rheum Dis 70(5):818\u2013822","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"707_CR17","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon\u00a0NN, Paterson\u00a0JM, Li\u00a0P, Inman\u00a0RD, Haroon\u00a0N (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Ann Intern Med 163(6):409\u2013416","journal-title":"Ann Intern Med"},{"issue":"11","key":"707_CR18","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland\u00a0G, Gran\u00a0JT, Nossent\u00a0JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921\u20131925","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"707_CR19","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde\u00a0D, Cheng-Chung\u00a0WJ, Dougados\u00a0M, Mease\u00a0P, Deodhar\u00a0A, Maksymowych\u00a0WP et al (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a\u00a0phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392(10163):2441\u20132451","journal-title":"Lancet"},{"issue":"6","key":"707_CR20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1136\/annrheumdis-2013-204963","volume":"74","author":"J Sieper","year":"2015","unstructured":"Sieper\u00a0J, Braun\u00a0J, Kay\u00a0J, Badalamenti\u00a0S, Radin\u00a0AR, Jiao\u00a0L et al (2015) Sarilumab for the treatment of ankylosing spondylitis: results of a\u00a0Phase II, randomised, double-blind, placebo-controlled study (ALIGN). Ann Rheum Dis 74(6):1051\u20131057","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"707_CR21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","volume":"73","author":"D Poddubnyy","year":"2014","unstructured":"Poddubnyy\u00a0D, Hermann\u00a0KG, Callhoff\u00a0J, Listing\u00a0J, Sieper\u00a0J (2014) Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a\u00a028-week, prospective, open-label, proof-of-concept study (TOPAS). Ann Rheum Dis 73(5):817\u2013823","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"707_CR22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/annrheumdis-2013-203559","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper\u00a0J, Porter-Brown\u00a0B, Thompson\u00a0L, Harari\u00a0O, Dougados\u00a0M (2014) Assessment of short-term symptomatic efficacy of tocilizumab in ankylosing spondylitis: results of randomised, placebo-controlled trials. Ann Rheum Dis 73(1):95\u2013100","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"707_CR23","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/art.27383","volume":"62","author":"IH Song","year":"2010","unstructured":"Song\u00a0IH, Heldmann\u00a0F, Rudwaleit\u00a0M, Listing\u00a0J, Appel\u00a0H, Braun\u00a0J et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a\u00a0twenty-four-week clinical trial. Arthritis Rheum 62(5):1290\u20131297","journal-title":"Arthritis Rheum"},{"issue":"10162","key":"707_CR24","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","volume":"392","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde\u00a0D, Baraliakos\u00a0X, Gensler\u00a0LS, Maksymowych\u00a0WP, Tseluyko\u00a0V, Nadashkevich\u00a0O et al (2018) Efficacy and safety of filgotinib, a\u00a0selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a\u00a0randomised, placebo-controlled, phase 2 trial. Lancet 392(10162):2378\u20132387","journal-title":"Lancet"},{"issue":"8","key":"707_CR25","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2016-210322","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde\u00a0D, Deodhar\u00a0A, Wei\u00a0JC, Drescher\u00a0E, Fleishaker\u00a0D, Hendrikx\u00a0T et al (2017) Tofacitinib in patients with ankylosing spondylitis: a\u00a0phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis 76(8):1340\u20131347","journal-title":"Ann Rheum Dis"},{"key":"707_CR26","unstructured":"(FDA) FaDA. FDA approves treatment for patients with a\u00a0type of inflammatory arthritis. 2019;2019(02 April 2019)."},{"issue":"7","key":"707_CR27","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1002\/art.40866","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar\u00a0A, Gensler\u00a0LS, Kay\u00a0J, Maksymowych\u00a0WP, Haroon\u00a0N, Landewe\u00a0R et al (2019) A\u00a0fifty-two-week, randomized, placebo-controlled trial of certolizumab pegol in nonradiographic axial spondyloarthritis. Arthritis Rheumatol 71(7):1101\u20131111. https:\/\/doi.org\/10.1002\/art.40866","journal-title":"Arthritis Rheumatol"},{"key":"707_CR28","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.181040","author":"J Braun","year":"2019","unstructured":"Braun\u00a0J, Baraliakos\u00a0X, Kiltz\u00a0U, Kruger\u00a0K, Burmester\u00a0GR, Wassenberg\u00a0S et al (2019) Disease activity cutoff values in initiating tumor necrosis factor inhibitor therapy in ankylosing spondylitis: A\u00a0german GO-NICE study subanalysis. J Rheumatol. pii:jrheum.181040. https:\/\/doi.org\/10.3899\/jrheum.181040","journal-title":"J Rheumatol"},{"issue":"1","key":"707_CR29","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","volume":"3","author":"A Sepriano","year":"2017","unstructured":"Sepriano\u00a0A, Regel\u00a0A, van der Heijde\u00a0D, Braun\u00a0J, Baraliakos\u00a0X, Landewe\u00a0R et al (2017) Efficacy and safety of biological and targeted-synthetic DMARDs: a\u00a0systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3(1):e396","journal-title":"RMD Open"},{"key":"707_CR30","first-page":"CD005468","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell\u00a0LJ, Zochling\u00a0J, Boonen\u00a0A, Singh\u00a0JA, Veras\u00a0MM, Tanjong Ghogomu\u00a0E et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD5468","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"707_CR31","first-page":"935","volume":"34","author":"I Olivieri","year":"2016","unstructured":"Olivieri\u00a0I, Fanizza\u00a0C, Gilio\u00a0M, Ravasio\u00a0R (2016) Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritis. Clin Exp Rheumatol 34(5):935\u2013940","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"707_CR32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/art.23333","volume":"59","author":"MS Heiberg","year":"2008","unstructured":"Heiberg\u00a0MS, Koldingsnes\u00a0W, Mikkelsen\u00a0K, Rodevand\u00a0E, Kaufmann\u00a0C, Mowinckel\u00a0P et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a\u00a0longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234\u2013240","journal-title":"Arthritis Rheum"},{"issue":"7","key":"707_CR33","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1136\/annrheumdis-2012-201933","volume":"72","author":"B Glintborg","year":"2013","unstructured":"Glintborg\u00a0B, Ostergaard\u00a0M, Krogh\u00a0NS, Tarp\u00a0U, Manilo\u00a0N, Loft\u00a0AG et\u00a0al (2013) Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor alpha inhibitor therapy: results from the Danish nationwide DANBIO registry. Ann Rheum Dis 72(7):1149\u20131155","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR34","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/art.24408","volume":"60","author":"N Barkham","year":"2009","unstructured":"Barkham\u00a0N, Keen\u00a0HI, Coates\u00a0LC, O\u2019Connor\u00a0P, Hensor\u00a0E, Fraser\u00a0AD et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946\u2013954","journal-title":"Arthritis Rheum"},{"issue":"1","key":"707_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/annrheumdis-2012-203201","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper\u00a0J, Lenaerts\u00a0J, Wollenhaupt\u00a0J, Rudwaleit\u00a0M, Mazurov\u00a0VI, Myasoutova\u00a0L et al (2014) Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1. Ann Rheum Dis 73(1):101\u2013107","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"707_CR36","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1136\/annrheumdis-2011-200358","volume":"71","author":"J Sieper","year":"2012","unstructured":"Sieper\u00a0J, van der Heijde\u00a0D, Dougados\u00a0M, Brown\u00a0LS, Lavie\u00a0F, Pangan\u00a0AL (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700\u2013706","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"707_CR37","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1136\/annrheumdis-2013-205133","volume":"75","author":"A Ciurea","year":"2016","unstructured":"Ciurea\u00a0A, Scherer\u00a0A, Weber\u00a0U, Exer\u00a0P, Bernhard\u00a0J, Tamborrini\u00a0G et\u00a0al (2016) Impaired response to treatment with tumour necrosis factor alpha inhibitors in smokers with axial spondyloarthritis. Ann Rheum Dis 75(3):532\u2013539","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"707_CR38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1093\/rheumatology\/kev392","volume":"55","author":"B Glintborg","year":"2016","unstructured":"Glintborg\u00a0B, Hojgaard\u00a0P, Lund Hetland\u00a0M, Krogh\u00a0SN, Kollerup\u00a0G, Jensen\u00a0J et al (2016) Impact of tobacco smoking on response to tumour necrosis factor-alpha inhibitor treatment in patients with ankylosing spondylitis: results from the Danish nationwide DANBIO registry. Rheumatology (Oxford) 55(4):659\u2013668","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"707_CR39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13075-017-1372-3","volume":"19","author":"R Micheroli","year":"2017","unstructured":"Micheroli\u00a0R, Hebeisen\u00a0M, Wildi\u00a0LM, Exer\u00a0P, Tamborrini\u00a0G, Bernhard\u00a0J et\u00a0al (2017) Impact of obesity on the response to tumor necrosis factor inhibitors in axial spondyloarthritis. Arthritis Res Ther 19(1):164","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"707_CR40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar\u00a0C, Scherer\u00a0A, Baraliakos\u00a0X, de Hooge\u00a0M, Micheroli\u00a0R, Exer\u00a0P et\u00a0al (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77(1):63\u201369","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"707_CR41","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon\u00a0N, Inman\u00a0RD, Learch\u00a0TJ, Weisman\u00a0MH, Lee\u00a0M, Rahbar\u00a0MH et\u00a0al (2013) The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65(10):2645\u20132654","journal-title":"Arthritis Rheum"},{"issue":"1","key":"707_CR42","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.40661","volume":"71","author":"JW Park","year":"2019","unstructured":"Park\u00a0JW, Kim\u00a0MJ, Lee\u00a0JS, Ha\u00a0YJ, Park\u00a0JK, Kang\u00a0EH et\u00a0al (2019) Impact of tumor necrosis factor inhibitor versus Nonsteroidal antiinflammatory drug treatment on radiographic progression in early Ankylosing Spondylitis: its relationship to inflammation control during treatment. Arthritis Rheumatol 71(1):82\u201390","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"707_CR43","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos\u00a0X, Listing\u00a0J, Brandt\u00a0J, Haibel\u00a0H, Rudwaleit\u00a0M, Sieper\u00a0J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450\u20131453","journal-title":"Rheumatology (Oxford)"},{"key":"707_CR44","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key375","author":"J Braun","year":"2018","unstructured":"Braun\u00a0J, Baraliakos\u00a0X, Deodhar\u00a0A, Poddubnyy\u00a0D, Emery\u00a0P, Delicha\u00a0EM et al (2018) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4\u2011year results from the MEASURE 1 study. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/key375","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"707_CR45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/annrheumdis-2017-212377","volume":"77","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde\u00a0D, Baraliakos\u00a0X, Hermann\u00a0KA, Landewe\u00a0RBM, Machado\u00a0PM, Maksymowych\u00a0WP et al (2018) Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4\u2011year imaging outcomes from the RAPID-axSpA phase III randomised trial. Ann Rheum Dis 77(5):699\u2013705","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"707_CR46","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/annrheumdis-2016-210023","volume":"76","author":"J Sieper","year":"2017","unstructured":"Sieper\u00a0J, Deodhar\u00a0A, Marzo-Ortega\u00a0H, Aelion\u00a0JA, Blanco\u00a0R, Jui-Cheng\u00a0T et al (2017) Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study. Ann Rheum Dis 76(3):571\u2013592","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"707_CR47","doi-asserted-by":"crossref","first-page":"e000749","DOI":"10.1136\/rmdopen-2018-000749","volume":"4","author":"J Braun","year":"2018","unstructured":"Braun\u00a0J, Deodhar\u00a0A, Landewe\u00a0R, Baraliakos\u00a0X, Miceli-Richard\u00a0C, Sieper\u00a0J et al (2018) Impact of baseline C\u2011reactive protein levels on the response to secukinumab in ankylosing spondylitis: 3\u2011year pooled data from two phase III studies. RMD Open 4(2):e749","journal-title":"RMD Open"},{"issue":"4","key":"707_CR48","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.ophtha.2012.09.040","volume":"120","author":"AD Dick","year":"2013","unstructured":"Dick\u00a0AD, Tugal-Tutkun\u00a0I, Foster\u00a0S, Zierhut\u00a0M, Liew\u00a0MSH, Bezlyak\u00a0V et al (2013) Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 120(4):777\u2013787","journal-title":"Ophthalmology"},{"issue":"12","key":"707_CR49","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","volume":"61","author":"W Hueber","year":"2012","unstructured":"Hueber\u00a0W, Sands\u00a0BE, Lewitzky\u00a0S, Vandemeulebroecke\u00a0M, Reinisch\u00a0W, Higgins\u00a0PD et al (2012) Secukinumab, a\u00a0human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a\u00a0randomised, double-blind placebo-controlled trial. Gut 61(12):1693\u20131700","journal-title":"Gut"},{"issue":"4","key":"707_CR50","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/annrheumdis-2018-214273","volume":"78","author":"S Schreiber","year":"2019","unstructured":"Schreiber\u00a0S, Colombel\u00a0JF, Feagan\u00a0BG, Reich\u00a0K, Deodhar\u00a0AA, McInnes\u00a0IB et\u00a0al (2019) Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a\u00a0retrospective analysis of pooled data from 21 clinical trials. Ann Rheum Dis 78(4):473\u2013479","journal-title":"Ann Rheum Dis"},{"issue":"10163","key":"707_CR51","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1016\/S0140-6736(18)31946-9","volume":"390","author":"D van der Heijde","year":"2018","unstructured":"van der Heijde\u00a0D, Cheng-Chung\u00a0WJ, Dougados\u00a0M, Mease\u00a0P, Deodhar\u00a0A, Maksymowych\u00a0WP et al (2018) Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a\u00a0phase 3 randomised, double-blind, active-controlled and placebo-controlled trial. Lancet 392(10163):2441\u20132451. https:\/\/doi.org\/10.1016\/S0140-6736(18)31946-9","journal-title":"Lancet"},{"issue":"4","key":"707_CR52","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","volume":"77","author":"S Glatt","year":"2018","unstructured":"Glatt\u00a0S, Baeten\u00a0D, Baker\u00a0T, Griffiths\u00a0M, Ionescu\u00a0L, Lawson\u00a0ADG et al (2018) Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a\u00a0randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis 77(4):523\u2013532","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"707_CR53","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/art.40579","volume":"70","author":"PJ Mease","year":"2018","unstructured":"Mease\u00a0PJ, Genovese\u00a0MC, Weinblatt\u00a0ME, Peloso\u00a0PM, Chen\u00a0K, Othman\u00a0AA et al (2018) Phase II study of ABT-122, a\u00a0tumor necrosis factor- and Interleukin-17A-targeted dual variable domain immunoglobulin, in patients with Psoriatic arthritis with an inadequate response to Methotrexate. Arthritis Rheumatol 70(11):1778\u20131789","journal-title":"Arthritis Rheumatol"},{"issue":"25","key":"707_CR54","doi-asserted-by":"crossref","first-page":"e7145","DOI":"10.1097\/MD.0000000000007145","volume":"96","author":"Z Ma","year":"2017","unstructured":"Ma\u00a0Z, Liu\u00a0X, Xu\u00a0X, Jiang\u00a0J, Zhou\u00a0J, Wang\u00a0J et al (2017) Safety of tumor necrosis factor-alpha inhibitors for treatment of ankylosing spondylitis: a meta-analysis. Medicine (Baltimore) 96(25):e7145","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"707_CR55","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.3892\/etm.2017.5003","volume":"14","author":"Z Xu","year":"2017","unstructured":"Xu\u00a0Z, Xu\u00a0P, Fan\u00a0W, Yang\u00a0G, Wang\u00a0J, Cheng\u00a0Q et al (2017) Risk of infection in patients with spondyloarthritis and ankylosing spondylitis receiving antitumor necrosis factor therapy: a meta-analysis of randomized controlled trials. Exp Ther Med 14(4):3491\u20133500","journal-title":"Exp Ther Med"},{"issue":"2","key":"707_CR56","doi-asserted-by":"crossref","first-page":"e000524","DOI":"10.1136\/rmdopen-2017-000524","volume":"3","author":"V Navarro-Compan","year":"2017","unstructured":"Navarro-Compan\u00a0V, Plasencia-Rodriguez\u00a0C, de Miguel\u00a0E, Diaz Del Campo\u00a0P, Balsa\u00a0A, Gratacos\u00a0J (2017) Switching biological disease-modifying antirheumatic drugs in patients with axial spondyloarthritis: results from a\u00a0systematic literature review. RMD Open 3(2):e524","journal-title":"RMD Open"},{"issue":"4","key":"707_CR57","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/annrheumdis-2017-212378","volume":"77","author":"A Molto","year":"2018","unstructured":"Molto\u00a0A, Etcheto\u00a0A, Gossec\u00a0L, Boudersa\u00a0N, Claudepierre\u00a0P, Roux\u00a0N et\u00a0al (2018) Evaluation of the impact of concomitant fibromyalgia on TNF alpha blockers\u2019 effectiveness in axial spondyloarthritis: results of a\u00a0prospective, multicentre study. Ann Rheum Dis 77(4):533\u2013540","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"707_CR58","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","volume":"76","author":"B Glintborg","year":"2017","unstructured":"Glintborg\u00a0B, Sorensen\u00a0IJ, Loft\u00a0AG, Lindegaard\u00a0H, Linauskas\u00a0A, Hendricks\u00a0O et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1\u2011year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426\u20131431","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"707_CR59","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.40516","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen\u00a0L, Huiskes\u00a0VJB, van den Bemt\u00a0BJF, Vriezekolk\u00a0JE, Teerenstra\u00a0S, van den Hoogen\u00a0FHJ et al (2018) Open-label, non-mandatory transitioning from originator Etanercept to Biosimilar SB4: six-month results from a\u00a0controlled cohort study. Arthritis Rheumatol 70(9):1408\u20131418","journal-title":"Arthritis Rheumatol"},{"issue":"10086","key":"707_CR60","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","volume":"389","author":"KK Jorgensen","year":"2017","unstructured":"Jorgensen\u00a0KK, Olsen\u00a0IC, Goll\u00a0GL, Lorentzen\u00a0M, Bolstad\u00a0N, Haavardsholm\u00a0EA et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a\u00a052-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304\u20132316","journal-title":"Lancet"},{"issue":"10","key":"707_CR61","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1093\/rheumatology\/kew269","volume":"55","author":"W Fong","year":"2016","unstructured":"Fong\u00a0W, Holroyd\u00a0C, Davidson\u00a0B, Armstrong\u00a0R, Harvey\u00a0N, Dennison\u00a0E et\u00a0al (2016) The effectiveness of a\u00a0real life dose reduction strategy for tumour necrosis factor inhibitors in ankylosing spondylitis and psoriatic arthritis. Rheumatology (Oxford) 55(10):1837\u20131842","journal-title":"Rheumatology (Oxford)"},{"issue":"10142","key":"707_CR62","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0140-6736(18)31362-X","volume":"392","author":"R Landewe","year":"2018","unstructured":"Landewe\u00a0R, Sieper\u00a0J, Mease\u00a0P, Inman\u00a0RD, Lambert\u00a0RG, Deodhar\u00a0A et al (2018) Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a\u00a0multicentre, randomised, double-blind study. Lancet 392(10142):134\u2013144","journal-title":"Lancet"},{"issue":"1","key":"707_CR63","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/annrheumdis-2013-203460","volume":"73","author":"J Sieper","year":"2014","unstructured":"Sieper\u00a0J, Lenaerts\u00a0J, Wollenhaupt\u00a0J, Rudwaleit\u00a0M, Mazurov\u00a0VI, Myasoutova\u00a0L et al (2014) Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a\u00a06-month, randomised, open-label follow-up study, INFAST Part 2. Ann Rheum Dis 73(1):108\u2013113","journal-title":"Ann Rheum Dis"},{"key":"707_CR64","first-page":"CD004800","volume":"11","author":"J Chen","year":"2014","unstructured":"Chen\u00a0J, Lin\u00a0S, Liu\u00a0C (2014) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 11:CD4800","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"707_CR65","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s10067-015-2937-7","volume":"34","author":"CE Althoff","year":"2015","unstructured":"Althoff\u00a0CE, Bollow\u00a0M, Feist\u00a0E, Marticorena-Garcia\u00a0SR, Eshed\u00a0I, Diekhoff\u00a0T et al (2015) CT-guided corticosteroid injection of the sacroiliac joints: quality assurance and standardized prospective evaluation of long-term effectiveness over six months. Clin Rheumatol 34(6):1079\u20131084","journal-title":"Clin Rheumatol"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00707-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00707-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T16:07:55Z","timestamp":1721750875000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00707-z"}},"subtitle":["Klinische Wirksamkeit","Clinical efficacy"],"short-title":[],"issued":{"date-parts":[[2019,9,17]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["707"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00707-z","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,17]]},"assertion":[{"value":"17 September 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"U.\u00a0Kiltz: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, Biocad, Chugai, Eli Lilly, Gr\u00fcnenthal, Janssen, MSD, Novartis, Pfizer, Roche und UCB. Forschungsunterst\u00fctzung (unrestricted grant) durch AbbVie, Biogen, Novartis und Pfizer und J.\u00a0Braun: Berater- und\/oder Referentenhonorare durch die Firmen AbbVie, Amgen, BMS, Boehringer, Celgene, Celltrion, Centocor, Chugai, EBEWE Pharma, Medac, MSD (Schering-Plough), Mundipharma, Novartis, Pfizer (Wyeth), Roche, Sanofi-Aventis, UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}